Pubmed (TDAH) du 08/02/26
1. Bou Sader Nehme S, Sánchez-Sarasúa S, Medrano MC, Bouchatta O, Bitar T, Alameddine A, Galineau L, Brunault P, Kerekes N, Sanchez-Perez AM, Hleihel W, Landry M. Erratum to « Animal models of attention-deficit/hyperactivity disorder: Diversity and validity » [Pharmacological Reviews 78 (2026) 100108]. Pharmacol Rev;2026 (Feb 6);78(2):100123.
Lien vers le texte intégral (Open Access ou abonnement)
2. Brynte C, Schellekens A, Konstenius M, Begeman AHA, Crunelle CL, Demetrovics Z, Dom G, Icick R, Johnson B, Kapitány-Fövény M, Levin FR, Luderer M, Matthys F, Moggi F, Palma-Álvarez RF, Ramos-Quiroga JA, Reif A, van Kernebeek MW, Vélez-Pastrana MC, van den Brink W, Franck J. Predictors of treatment success in patients with substance use disorder (SUD) and co-morbid attention deficit/hyperactivity disorder (ADHD): Results from the International Naturalistic Cohort Study of ADHD and SUD (INCAS). Eur Neuropsychopharmacol;2026 (Feb 6);106:112783.
Comorbid attention deficit/hyperactivity disorder (ADHD) and substance use disorder (SUD) is associated with poor treatment outcomes. This international multi-center observational prospective cohort study aimed to gain knowledge about predictors of treatment outcomes in adult SUD+ADHD patients. Data was collected from June 2017 to May 2021 at baseline, four weeks, three months, and nine months at twelve treatment services in nine countries. Main outcomes were: Treatment retention, ≥30% reduction from baseline to follow-up according to the adult ADHD self-report scale (ASRS-18), and self-reported substance use at three-month follow-up. A total of 137 adult females (24 %) and 441 adult males (76 %) were enrolled. Receiving stimulant treatment for ADHD was significantly associated with better treatment retention (OR: 2·4, 95% CI: 1·4-4·2), ≥30% reduction in ASRS total score (OR: 2·6, 95% CI: 1·2-6·1), and fewer heavy drinking days (IRR: 0·24, 95% CI: 0·13-0·42) at three months. Psychosocial treatment for ADHD was independently and significantly associated with fewer heavy drinking days at three months (IRR: 0·27, 95% CI: 0·14-0·51). In summary, treatment of ADHD in SUD+ADHD patients was related to improvements in ADHD-symptoms, treatment retention and fewer heavy drinking days at follow-up. These findings highlight the importance of ADHD treatment provision in this population. Future RCTs are warranted to confirm these results and should assess combinations of ADHD treatments and SUD treatments using different doses of stimulants. Trial Registration: ISRCTN (https://doi.org/10.1186/ISRCTN15998989).
Lien vers le texte intégral (Open Access ou abonnement)
3. Gao T, Wei Z, Liang G, Zhao P, Wang L, Fan Y. The fNIRS Landscape of ADHD: Device Specifications, Neural Markers, and AI Classification. Ann N Y Acad Sci;2026 (Feb);1556(1):e70209.
This systematic review synthesizes 69 original studies (2019-2025) to evaluate the transformative potential of functional near-infrared spectroscopy (fNIRS) in ADHD research. As a portable, motion-tolerant neuroimaging tool, fNIRS enables robust measurement of cortical hemodynamic activity during cognitive tasks. We first consolidate the specifications of fNIRS devices employed in ADHD studies. Next, we discuss the neural markers derived from fNIRS data-including hemodynamic response function features, functional connectivity metrics, the beta coefficients of general linear model, graph theory measures, amplitude of low-frequency fluctuations, and multiscale entropy-alongside artificial intelligence (AI) algorithms achieving high diagnostic accuracy. Critically, we demonstrate fNIRS’s utility in objectively monitoring treatment response, as evidenced by prefrontal cortex normalization and posterior activation modulation following interventions. To realize personalized diagnostics and therapeutics, future research should prioritize: (1) wearable fNIRS systems for ecological monitoring, (2) multimodal AI frameworks integrating fNIRS with behavioral/genetic data, and (3) standardized protocols validated in large-scale cohorts.
Lien vers le texte intégral (Open Access ou abonnement)
4. Morandini HAE, Vos SB, Bhoyroo R, Jacques A, Rao P. Clinical and cognitive profile of nigral iron content in children with ADHD. J Affect Disord;2026 (Feb 5);402:121329.
BACKGROUND: ADHD has been associated with impaired central nervous dopaminergic pathways. Brain iron is an essential cofactor for the synthesis of dopamine and the substantia nigra (SN) is a significant pool of dopaminergic neurons playing a central role in the activity of the nigrostriatal pathway. The present study investigated SN iron content in children with ADHD, its relationship with ADHD symptom severity and cognitive performance. METHODS: Neuroimaging and phenotypical data were extracted from the Healthy Brain Network dataset. After initial screening, 54 medication-naïve children with ADHD and 44 neurotypical (NT) children (8-12 year) were included. ADHD symptom severity was extracted from the Child Behavior Checklist (CBCL) Parent report and working memory (WM) and inhibitory control scores from the National Institute of Health toolbox. RESULTS: A mixed between-within subjects ANOVA revealed no significant difference in SN iron content between medication-naïve children with ADHD and NT (partial eta squared = 0.001, p = .79). In the ADHD group, Spearman’s correlation revealed a significant inverse relationship between left (r = -0.38; p < .01) and right (r = -0.33; p = .01) SN iron content and CBCL Attention Problems T score, while in the NT group left SN iron content significantly correlated with inhibitory control (r = 0.36; p = .02). CONCLUSIONS: Although there was no difference in nigral iron content between both groups, higher SN iron content was associated with lower attention problems in children with ADHD and higher SN iron content was associated with better inhibitory control in NT children.
